Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis
Open Access
- 7 January 2021
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (2), 351-362
- https://doi.org/10.3324/haematol.2020.248542
Abstract
Activated factor VII (FVIIa), the first protease of clotting, expresses its physiological procoagulant potential only after complexing with tissue factor (TF) exposed to blood. Deep knowledge of the FVIIa-TF complex and F7 gene helps to understand the Janus-faced clinical findings associated to low or elevated FVII activity (FVIIc). Congenital FVII deficiency, the most frequent among the recessively inherited bleeding disorders, is caused by heterogeneous mutations in the F7 gene. Complete FVII deficiency causes perinatal lethality. A wide range of bleeding symptoms, from life-threatening intracranial hemorrhage to mild mucosal bleeding, is observed in patients with apparently modest differences in FVIIc levels. Though clinically relevant FVIIc threshold levels are still uncertain, effective management, including prophylaxis, has been devised, substantially improving the quality of life of patients. The exposure of TF in diseased arteries fostered investigation on the role of FVII in cardiovascular disease. FVIIc levels were found to be predictors of cardiovascular death and to be markedly associated to F7 gene variation. These genotype-phenotype relationships are among the most extensively investigated in humans. Genome-wide analyses extended association to numerous loci that, together with F7, explain >50% of FVII level plasma variance. However, the ability of F7 variation to predict thrombosis was not consistently evidenced in the numerous population studies. Main aims of this review are to highlight i) the biological and clinical information that distinguishes FVII deficiency from the other clotting disorders and ii) the impact exerted by genetically predicted FVII level variation on bleeding as well as on the thrombotic states.This publication has 113 references indexed in Scilit:
- Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)Haematologica, 2013
- Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery DiseaseAmerican Journal of Human Genetics, 2012
- Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiencyHaematologica, 2011
- A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) ConsortiumHuman Molecular Genetics, 2011
- Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsJournal of Thrombosis and Haemostasis, 2010
- Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK menJournal of Thrombosis and Haemostasis, 2010
- Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VIIHaematologica, 2010
- Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand FactorJournal of the American College of Cardiology, 2010
- Heightened Thrombin Formation but Normal Plasma Levels of Activated Factor VII in Patients With Acute Coronary SyndromesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Coagulation Factor VII Mass and Activity in Young Men With Myocardial Infarction at a Young AgeArteriosclerosis, Thrombosis, and Vascular Biology, 1995